Duke Virology Quality Assurance

VQA

HIV-1 Drug Resistance Sequencing
Participation Requirements and Scoring Procedures

Thomas Denny MSc, M.Phil., Principal Investigator
Raul Louzao, MPA Laboratory Operations Director
Miranda Carper, PhD VQA Program Manager
Terese Camp, VQA Program Manager
Salvatore Scianna, QCM Director

National Institute of Allergy and Infectious Diseases
## Contents

VQA Program HIV-1 Drug Resistance Proficiency Testing Requirements .......................... 2
  Introduction to Participation Requirements ................................................................. 2
  Proficiency Testing Overview: ....................................................................................... 2
  VQA Participation Requirements .................................................................................. 3
    New Laboratory Certification Testing ........................................................................ 3
    New Assay Enrollment and Certification .................................................................... 4
  Maintaining Approval for Protocol Testing ................................................................. 4
  Withdrawal/Removal ..................................................................................................... 5
  Recertification ................................................................................................................ 6
  Appeals ............................................................................................................................ 6
  Practice Panels .............................................................................................................. 6
  Change in Status Letters .............................................................................................. 6
VQA Program HIV-1 Drug Resistance Sequencing Proficiency Testing Scoring Procedure ......... 7
  Introduction to PT Scoring ............................................................................................ 7
  Scoring Criteria for VQA HIV-1 Drug Resistance Proficiency Testing ......................... 7
    Technical Performance: Three stages of Scoring ..................................................... 7
    Specifying the Consensus Sequence ......................................................................... 8
    A Model for Assessing Performance ......................................................................... 9
    Determining the Performance Score ......................................................................... 10
    Non-Technical Performance ...................................................................................... 11
VQA Program HIV-1 Drug Resistance Proficiency Testing Requirements

Introduction to Participation Requirements

The National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS/DAIDS (DAIDS) Virology Quality Assurance (VQA) Program provides quality assurance and proficiency testing to labs that are performing virologic-based assays for HIV and other pathogens in support of NIAID-funded clinical trials. All laboratories that intend to do HIV-1 drug resistance testing (DR) to identify mutations in the reverse transcriptase, protease and integrase gene regions for NIAID-funded clinical trials must have an approved status in the VQA Genotypic (GEN) HIV-1 Drug Resistance Sequencing proficiency testing program.

Participation in the real-time testing phase of the program can only occur after the successful testing of two five-member panels or completion of an assay validation. VQA GEN HIV-1 DR proficiency testing panels (5 samples) are to be run every six months. The following sections detail the requirements to obtain and maintain approval to participate in DR proficiency testing for NIH-funded protocols.

Proficiency Testing Overview:

Labs enrolled in the Duke VQA Program are shipped 5-member plasma panels twice per year. Laboratories with a WHO-only affiliation receive 5-member plasma panels once per year. Each panel will be named using the following format:

- DNYYYYY_MM.01-05A-E,
  - GEN = PT program
  - YYYY = year of the PT
  - MM = month of PT shipment
  - 01-05 = sample number
  - A-E = panel configuration

The VQA will provide laboratories with a 5-member PT panel composed of Basematrix 53 Diluent (a defibrinated EDTA plasma produced by SeraCare) spiked with well-characterized HIV-1 virus culture supernatants or virus from infectious molecular clones (IMCs). The viruses will have known HIV-1 drug resistance mutations in the protease (PR; amino acids 9-94), reverse transcriptase (RT; amino acids 40-237) or integrase (INT; amino acids 50-264) genes. Each laboratory must submit a specimen information and mutation file (an EXCEL spread sheet developed by the VQA) and the FASTA/sequence text file for each specimen to the VQA for analyses. Data for the PT is submitted to the VQA for analysis using the Duke VQA Web Application https://vqaapp.dhvi.duke.edu/users/login. Please email the Duke VQA at vqa-gen@duke.edu to register for the web system. The Duke VQA Biostatisticians will analyze data for each PT. Panels will be assessed for sequence homology and mutation calls. Scoring criteria for the VQA GEN HIV-1 DR proficiency testing program is found below in the Scoring Procedure section. Scores for each PT will be provided after each round of testing in a report that will be distributed to the participating laboratories via the Duke VQA Web Application.
VQA Participation Requirements

New Laboratory Certification Testing

Participation in any VQA proficiency testing program must be approved by the VQA Contracting Officer Representative (COR, aka Project Officer). In order to be considered for participation in the VQA Program, a new laboratory must be doing HIV-1 drug resistance testing for an NIH-funded program. Once approved, the new laboratory will need to complete an application for participation in the program that will outline the programs of interest and provide laboratory contact information. A new VQA laboratory number will be assigned to each VQA laboratory to uniquely identify that laboratory within the program.

The VQA GEN HIV-1 DR proficiency testing program currently evaluates assay performance for RT, PR, and INT gene regions. RT and PR genes are evaluated together, and the INT gene region is evaluated separately. Laboratories may opt to participate in one or both programs. Participation rules are the same regardless of the gene region being evaluated.

The VQA program accepts data for genotypic HIV-1 drug resistance testing generated using commercially available and internally developed assays (IH). Sequence files must be submitted to the VQA via the Duke VQA Web Application https://vqaapp.dhvi.duke.edu/users/login. All new laboratories must register with the Duke VQA. To register, email the Duke VQA at vqa-gen@duke.edu in order to gain access to the VQA Web Application. Information regarding panel labeling requirements and rules for data submission will be provided to the testing laboratory through the VQA Web System and/or email when panels are shipped for testing.

In order to achieve an Approved status for genotypic HIV-1 drug resistance testing, a laboratory must run and pass four (4) five-member panels, or perform an assay validation and run and pass two (2) five-member panels. Panels may be tested during regular rounds of proficiency testing, which occurs two times per year, or it may be “Fast-Tracked” using historical panels that have been pre-tested in the field. Since consensus sequences are derived using data generated in the field, previous validation of the samples testing is required.

A laboratory must pass two (2) five-member panels or successfully complete an assay validation in order to prequalify and to become provisionally approved for protocol testing. Panels must be tested as five-member panels and submitted for scoring after each panel is tested. The results of the analysis should be reviewed before the next panel is tested in order to identify problems early in the process. A score of “C” is required for both prequalification panels in order for the laboratory to be deemed provisionally approved. If a score of “PC” is obtained on the second prequalification panel, then a laboratory would need to obtain a score of “C” on the third panel in order to be provisionally approved. A subsequent score of a “PC” or a single score of “P” on the third prequalification panel would require intervention by the VQA laboratory prior to testing any additional panels.

Once the prequalification phase is completed, a laboratory will need to pass two additional panels to become fully approved. The prequalification and approval testing may be done during normal track testing (panels will be received every six months) or fast-tracked using stored panels, previously used for proficiency testing. **Note: the VQA will provide a rating for each laboratory based on the results of pre-qualification and ongoing proficiency testing. However, the approval for protocol testing is defined at the network level and thus approval ratings may require additional testing as deemed necessary by the individual networks.**

VQA Testing Requirements for HIV Drug Resistance Proficiency Testing
Version 2.0: 15 October 2021

3
Cumulative ratings will be assessed as with other VQA proficiency testing programs, though for this program, the prequalification panels will be included in the cumulative scoring. A laboratory's performance rating (PR) is based on the sum of the scores for the four most recent proficiency panels (Performance Score, PS). Individual proficiency panels are scored a “1” for a Certified (C), “2” for a Provisionally Certified (PC), “4” for a Probation (P) and “4” for No Data submitted (ND). The Performance Score (PS) results in a Performance Rating (PR) are assigned as listed in Table 1 below.

Table 1: VQA Performance Ratings

<table>
<thead>
<tr>
<th>ASSESSMENT</th>
<th>PS</th>
<th>PR</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPROVED</td>
<td>4-6</td>
<td>A</td>
<td>Eligible for protocol testing</td>
</tr>
<tr>
<td>PROVISIONALLY APPROVED</td>
<td>7-9</td>
<td>PA</td>
<td>Eligible for protocol testing at discretion of protocol virologist</td>
</tr>
<tr>
<td>NOT APPROVED</td>
<td>10-13</td>
<td>NA</td>
<td>Not eligible for protocol testing</td>
</tr>
</tbody>
</table>

A new laboratory must obtain an APPROVED performance rating prior to performing any protocol testing. A laboratory will be fully approved for testing after two real-time proficiency testing panels if a score of “C” is obtained on both. If a score of “P or PC” is obtained on the first real-time panel after certification, then the approval rating will be based on the cumulative score obtained by the laboratory once a total of 4 panels (including prequalification and real-time proficiency testing) have been tested. Any score of “P” on a panel tested after qualification would require a laboratory to run and pass (with a score of “C”) two 5-member panels before full approval may be (re)achieved. This reapproval process may be fast-tracked using stored panels. If a laboratory receives a score of PC or P for a PT, they will receive an Investigation Report (IR) that is to be reviewed and filled out by the laboratory. The IR form helps guide the lab in determining the root cause of the score for that PT.

New Assay Enrollment and Certification

A laboratory may request to:

- Obtain approval for protocol testing using multiple platforms
- Switch platforms
- Certify additional instruments for VQA certified assays

All new assays and instruments enrolled in the VQA program need to be certified following the procedures outlined in the above section, New Laboratory Certification Testing. The VQA permits the use of two different assays/platforms; laboratories must obtain special approval from the VQA if they wish to become certified using more than two different assays. Each assay added to the VQA Program will be certified separately and the rules for achieving an APPROVED rating applies to all assays used within a laboratory.

The Duke VQA can assist in assay and instrument validations. Please contact the Duke VQA (vqa-gen@duke.edu) for more information about assay requirements or to request a validation plan and data submission template.

Maintaining Approval for Protocol Testing

To maintain an APPROVED certification status, a laboratory must participate in two rounds of real-time proficiency testing per year as scheduled by the VQA. Additionally, cumulative certification
ratings based on the sum of the scores from the four most recent rounds of testing (see Table 1 above) is used to determine the labs eligibility for protocol testing. Below is a list of PT scores and the associated point values:

- C (certified) = 1 point
- PC (provisionally certified) = 2 points
- P (probation) = 4 points

Additional points will be added if a laboratory received a non-technical penalty for data timeliness, data query responsiveness, data submissions containing PHI and/or PII, or for data entry errors that are not corrected by the laboratory prior to the PT due date (See Non-Technical Performance section below for additional details).

If a laboratory has a decline in status from approved to provisionally approved due to their cumulative score they would need to run and pass (with a score of C) two five-member panels before they can be fully approved for testing. Additionally, any score of "P" on a panel tested after qualification would require a laboratory to run and pass (with a score of “C”) two 5-member panels before full approval may be (re)achieved. The reapproval process may be fast-tracked using stored PT panels.

If a lab is unable to participate in a PT testing round or submit data by the PT due date, the laboratory must contact the Duke VQA and request an exemption (not submit data for that round of testing), to be placed on hold, or extension. Duke VQA must approve all requests to be placed on hold or for exemptions and extensions. Only one exemption per four PTs can be granted to a participating site. Extensions may be granted for up to three weeks past the stated deadline for the PT. A laboratory may request an extension or exemption for reasons such as:

1. Panel stuck in customs
2. Delay of shipment
3. Panel was thawed upon receipt
4. Panel was lost during shipping
5. Reagents for analysis are backordered or delayed
6. Instrument was broken
7. Contamination of sample
8. Laboratory closures
9. Laboratory accident (i.e. vials dropped and contents spilled)

A laboratory may request to be placed ‘on hold’ for up to 12 months without penalty (see section below on withdrawal from the program). Laboratories that are placed on hold for more than 6 months will be expected to run and pass the two most recent 5-member panels upon re-entering the program. Network approval must be obtained prior to resuming protocol testing.

Withdrawal/Removal

A laboratory may voluntarily withdraw from the VQA GEN HIV-1 DR proficiency testing program at any time. A laboratory may also request to be placed ‘ON HOLD’ as a result of operational circumstances (e.g. personnel problems, laboratory issues, etc.) for up to 12 months. A laboratory may not perform protocol testing while the laboratory is ‘ON HOLD’. A laboratory that has not participated in the VQA GEN HIV-1 DR proficiency testing program for more than 12 consecutive months will automatically be removed from the program.
Recertification

If a laboratory wishes to re-enter the HIV-1 drug resistance proficiency testing program after removal, being on hold for longer than 12 months, or has ongoing problems with proficiency panels, the laboratory will need to be re-qualified as a new laboratory (see section above).

“B-E” panel configurations will be created for each round of testing to permit retesting in the event of problems. Re-approval status may be attained after failure of a panel by obtaining two scores of “C” on two consecutive panels after the first failure. This may be achieved by running a “B” panel configuration for the panel that failed and running the next scheduled panel send-out (two 5-member panels must be completed and passed within 6 months of the first failure). Additionally, other archived panels may be tested if a laboratory wishes to recertify before the next scheduled panel send-out.

Appeals

The VQA recommends scoring for proficiency panels based on the criteria defined for the program. The VQA Advisory Board (VQAAB) then reviews the scoring for each round of testing for labs that had a decline in status or had a problem that does not follow the VQA PT rules (the laboratory identities are blinded for this process). Any laboratory may appeal the score on a proficiency panel by submitting a letter or email to William Meyer III, Chair of the VQAAB (william.a.meyer@questdiagnostics.com). All appeals will be reviewed by the VQAAB to determine if a change in scoring is indicated. Laboratories will be notified of the outcome of all appeals.

Practice Panels

Any laboratory may obtain retrospective HIV drug resistance proficiency panels prior to enrollment in the program, or at any time during their participation in the VQA program. Once a panel has been tested and analyzed as a ‘practice’ panel, it cannot be reclassified for use in laboratory certification. Results from these ‘practice’ panels will be assessed and results returned to the laboratory, but no certification score will be assigned.

Change in Status Letters

A laboratory will receive a change in status letter if they obtain a score on a round of testing that changes their overall performance rating. This letter will document the laboratory’s scores over the last four rounds of testing and will indicate when a change in status (performance rating) has resulted. A copy of this letter will be sent to the director of the laboratory and the network laboratory group for whom the laboratory does testing, as appropriate. Letters will be sent to notify individuals of both negative and positive changes in approval ratings. The VQA submits the letters on behalf of the VQAAB, but has no control over the implementation of rules governing the ability of a site to continue protocol testing. All questions surrounding a laboratory’s ability to resume or discontinue protocol testing should be directed to the respective network laboratory group or leadership.
VQA Program HIV-1 Drug Resistance Sequencing Proficiency Testing Scoring Procedure

Introduction to PT Scoring

Proficiency at genotypic HIV-1 drug resistance testing is assessed by comparing the sequences produced in each participating laboratory with the consensus sequences that are formed by combining data across participating laboratories. Proficiency scoring is limited to the regions of protease and reverse transcriptase (PR and RT respectively) that are used by the International AIDS Society-USA to select mutations that are or may be relevant in evaluating therapeutic efficacy (PR – amino acids 9-94; RT – amino acids 40-237) or the integrase gene (INT – amino acids 50-257). For the RT, PR and INT gene regions, a separate consensus sequence is defined for each sample using all available data sets from a round of testing. The consensus is obtained from a program developed by the Duke VQA biostatistics team.

The consensus sequence was chosen as a basis for proficiency scoring because the proficiency panels consist of clinical samples with unknown true sequences. Proficiency scores are based on the number of disagreements with the consensus sequences (herein referred to as errors). The protease and reverse transcriptase sequences from each sample are scored separately. Scores are summed over the 2 genes and 5 samples for RT and PR and over the one gene and five samples for INT to produce the total score for a laboratory.

Scoring Criteria for VQA HIV-1 Drug Resistance Proficiency Testing

The statistical framework for proficiency assessment for gene sequencing is very similar to the approaches that were used to develop other proficiency testing programs under the VQA Program. First, errors are assumed to occur randomly according to a specified probability distribution with parameters that are specific to each sample, gene and kit. Then, the probability of achieving or exceeding an observed error count is calculated from the assumed distribution. Error counts that are associated with low probabilities are flagged as being unlikely to have occurred by chance; i.e. error counts that have low probabilities of occurring by chance will be interpreted as evidence of performance problems.

Technical Performance: Three stages of Scoring

This general framework is used to score each RT and PR or INT sequence in three stages. First, the total number of errors in a sequence is scored. Second, the total number of “Complete Mismatch” errors in a subset of types of errors that is defined below is scored. Third, the total number of errors in identifying amino acids at resistance-associated codons is scored. Scoring at the third stage is limited to the resistance-associated codons within the RT, PR, and INT genes that are identified in the most current edition of the IAS-USA guidelines.

The subset of errors for performance assessment at the second stage was defined by inspecting the results from early proficiency panels to determine the types of errors made on the panels. The list of observed errors was expanded to include some others that were plausible but had not occurred yet. The following three classes of errors were identified.

1. Classes of Errors for Stage II of Scoring: Partial Mismatches

One common type of error is a disagreement between a single nucleotide at a given position in the consensus sequence versus a mixture that included this nucleotide in the submitted sequence (e.g. A
VQA T

Testing Requirements for HIV Drug Resistance Proficiency Testing
Version 2.0: 15 October 2021

8

vs. IUB code R). The reverse – a mixture in the consensus sequence versus a single nucleotide that is part of the mixture in the sequence from a laboratory – can also occur. More complicated situations, such as a two-part mixture in the consensus versus a three-part mixture that includes the consensus mixture can also occur (e.g. IUB code R vs. IUB code D). All of these are considered partial mismatches.

2. Classes of Errors for Stage II of Scoring: Complete Mismatches

The most common example of a complete mismatch is a disagreement between a nucleotide in the consensus sequence and the corresponding nucleotide in the sequence from a laboratory (e.g. A versus G). More complicated mismatches do occur, such as a two-part mixture in the consensus sequence versus a single nucleotide that is not part of the mixture (e.g. R vs. T). An insertion that is reported by a laboratory but not included in the consensus sequence, or a missed insertion that is included in the consensus sequence but not reported by a laboratory, would also be categorized as a complete mismatch.

3. Classes of Errors for Stage II of Scoring: Missing Data

In some cases, an entire sequence was missing. In others, part of the sequence was missing. A call of 'N' at a given position in the sequence from a laboratory would also be considered to be missing data if the consensus was something else.

The second stage of scoring is limited to the complete mismatches. The idea at this stage is to evaluate the quality of sequencing given that sequence data were obtained. Partial mismatches are excluded because they may reflect performance characteristics of the kits or minor variants in the sample so additional weight for this mismatch is not warranted. Missing data are excluded so that this stage of the analysis focuses on sequences that were actually obtained.

When proficiency scoring for HIV genotyping was discussed with ACTG virologists, several expressed interest in focusing on resistance codons. This interest motivated the scoring approach described here. The total proficiency score for each sequence in a laboratory is based on a weighted sum of the scores at the three stages. In effect, this approach gives greater weight to complete mismatches than to the other types of errors and greater weight to errors that alter amino acids at resistance-associated codons than to errors that don't alter these amino acids or that occur elsewhere in the sequence.

Specifying the Consensus Sequence

For purposes of scoring, a nucleotide position is included in the consensus sequence only if there is at least 80% agreement for that position among the laboratories. If agreement is less than 80%, then that position is excluded from the performance assessment. Agreement is strictly defined. A call of a single nucleotide in one laboratory and a mixture that includes that nucleotide in another is considered a disagreement. A mixture of two or more nucleotides is considered the consensus only if at least 80% of sequences include the same mixture at that position. Cases that could be considered mixtures, such as those in which, say, half the sequences include one nucleotide at a given position and the other half include a different nucleotide at that position are not considered mixtures for purposes of defining the consensus.

Experience with the first few proficiency panels indicated that very few positions would be excluded from scoring under this approach. Agreement reached at least 97% on both RT and PR genes in each of the five samples over each of the first five proficiency panels. This was true both for nucleotides
over the entire sequence expected from each kit and for amino acids at resistance-associated codons. The same approach was adopted for scoring of sequences in the INT gene.

**A Model for Assessing Performance**

Under the assumptions that sequencing errors in a given gene on a given sample are both rare and randomly distributed among nucleotide positions and laboratories, the number of errors in the sequence from a laboratory follows a Poisson distribution with unknown parameter \( \theta \), where \( \theta \) is the expected number of errors per sequence. As noted earlier, a p-value is assigned to each observed error count that represents the probability of obtaining at least the observed number of errors by chance in a random sample from a Poisson distribution with parameter \( \theta \). Error counts with p-values below 0.05 or 0.01 are flagged as mild or serious problems respectively.

An estimate of \( \theta \) is obtained from the data. Under the assumption of randomly distributed errors, the average error count, across all laboratories in which the same kit was used, is an unbiased estimate of \( \theta \). However, performance problems that would result in high error totals could inflate the average error count, which would bias the estimate of \( \theta \). Therefore, the frequency distribution of error counts for each gene in each sample will be examined to determine if there are error counts that are high enough to bias the estimate of the binomial parameter. Under the assumptions made here, these high error counts will appear to be outliers relative to the values that would be expected in a random sample from a Poisson distribution. If such outliers are identified, then the Poisson parameter is estimated after the outliers have been excluded. Otherwise, the parameter is estimated from the complete data.

Inspection of the data from early proficiency panels indicated that bias caused by outliers was an uncommon problem that has relatively little impact on the results of proficiency testing. This conclusion was based on a comparison of the range of error counts that would be flagged in data sets that included one outlier each and the range that would be flagged if the outlier were excluded. For example, suppose the average rate over 15 laboratories was 2.33 errors/sequence and that one sequence from one laboratory included 14 of those errors. Then, the average error rate, excluding this laboratory would be 1.5 errors/sequence. A data set with 5 errors would not be flagged if the parameter estimate included the outlier but would be flagged if the outlier was excluded from the parameter estimate. However, data sets with 4 or few errors would not be flagged in either case while data sets with 6 or more would be flagged in both cases. This is a rather small change in the cut point for determining proficiency. If the outlying data set included 21 errors, then the estimated Poisson parameter after excluding the outlier would be 1.0 and any data set with at least 4 errors would be flagged. Again, this is a small change in the cut point for proficiency testing.

In using the approach to performance assessment that is described here, care must be taken to avoid flagging error counts that are so low that they would otherwise be considered acceptable. Suppose, for example, that a set of PR sequences from the ViroSeq kit included one disagreement with the consensus in every three sequences, giving an average error count of 0.33 per sequence. Then, under the Poisson sampling model, a sequence with only two errors in 297 positions (99.3% agreement) would be flagged as having too many errors. Results from Proficiency Panels 002g, 003g, 004g and 005g indicated that this problem was likely to occur. The 25th percentile of 0.30 errors per sequence for PR on the ViroSeq kit was very close to the average error count used in the example above. If this value were treated as an estimate of the Poisson parameter then any error count greater than approximately one per sequence would be flagged.
This problem can be avoided if a threshold error rate can be defined such that error rates which are no greater than the threshold will be considered acceptable regardless of the p-value from the Poisson model. A threshold of greater than 1% agreement with the consensus is used. That is, a sequence will be flagged only if the error rate is greater than 1% and the p-value from the binomial model is < 0.05. The threshold error rate of 1% was derived from inspection of results from the coded replicates that were included on panels 002g-005g. In taking this approach, it was assumed that the rate of disagreement with a consensus sequence will generally be equal to or greater than the rate of disagreement between replicates of the same sample within a laboratory; i.e. inter-laboratory variation will generally be at least as great as intra-laboratory variation. Complete intra-laboratory agreement between replicate sequences was relatively uncommon. However, rates of agreement of at least 99% were achieved in the majority of cases for both genes sequenced on both kits. This same rule is applied regardless of the gene being analyzed.

In summary, performance on HIV gene sequencing panels is assessed by assigning a p-value to the observed number of disagreements between the sequence produced in a laboratory and the consensus for that gene in that sample across all laboratories in which the same kit was used. The p-values are derived from a Poisson sampling model under the assumption that disagreements with the consensus are randomly distributed among positions and laboratories. A separate Poisson parameter and separate cut points for assigning p-values is determined for each gene, sample and kit on the assumption that rates of disagreement are likely to depend on all three variables. Error rates < 1% are not be flagged as problematic even if the p-value for such a rate on a given sample is low enough to signal a problem.

**Determining the Performance Score**

For RT and PR, the results from the three stages of scoring described above are combined to produce a total score by first assigning points for the results to each sequence at each stage and then summing the points across stages, sequences and samples within a laboratory. For INT, the results from the three stages of scoring described above are combined to produce a total score by first assigning points for the results to each sequence at each stage and then summing the points across stages, sequences and samples within a laboratory. Points are assigned for PR/RT and INT using the algorithm summarized in Table 2.

For PR and RT gene regions, the resulting scores have a theoretical range of 0-40 (0-4 points per sequence X 2 sequences/sample X 5 samples/panel). For example, complete failure on one of 5 samples would produce a score of 8 points. The total scores are divided into three groups using two cut points. Total scores ≤ 7 receive performance scores of C, total scores from 8 to 14 receive performance scores of PC and total scores of at least 15 receive performance scores of P (see Table 3).

For INT gene region, the resulting scores have a theoretical range of 0-20 (0-4 points per sequence X 1 sequences/sample X 5 samples/panel). For example, complete failure on one of 5 samples would produce a score of 4 points. The total scores are divided into three groups using two cut points. Total scores < 4 points receive performance scores of C, total scores of 4 to 7 points receive performance scores of PC and total scores of at least > 7 receive performance scores of P (see Table 3).
Table 2: Genotypic HIV Drug Resistance Proficiency Criteria and Targets

<table>
<thead>
<tr>
<th>CRITERIA</th>
<th>DESCRIPTION</th>
<th>PERFORMANCE SCORE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Nucleotide Errors</td>
<td>Total errors on nucleotide calls as compared to the consensus sequence</td>
<td>2 points if $p \leq 0.01$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 point if $0.01 &lt; p \leq 0.05$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 points if $p &gt; 0.05$</td>
</tr>
<tr>
<td>Mismatches</td>
<td><strong>Partial Mismatches</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Submitted sequence mixture includes a disagreement in a single nucleotide at</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a given position when compared to the consensus</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Complete Mismatches</strong></td>
<td>1 point if $p \leq 0.01$</td>
</tr>
<tr>
<td></td>
<td>Submitted sequence includes a disagreement between a nucleotide in the</td>
<td>0 points if $p &gt; 0.01$</td>
</tr>
<tr>
<td></td>
<td>consensus sequence</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Missing Data</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Full or partial sequence is missing from submission</td>
<td></td>
</tr>
<tr>
<td>Amino Acid Calls</td>
<td>Total errors in identifying amino acids at resistance-associated codons</td>
<td>1 point if $\geq 2$ disagreements with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 points if $\leq 1$ disagreement with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>consensus</td>
</tr>
<tr>
<td>Total Points</td>
<td>C</td>
<td>0-40</td>
</tr>
</tbody>
</table>

*insertions and deletions will receive the maximum penalty of four errors, reflecting the large amount of mismatches caused by the subsequent frameshift

Table 3: Proficiency Scoring

<table>
<thead>
<tr>
<th>RATING</th>
<th>PERFORMANCE SCORE</th>
<th>SCORE RANGE PR/RT</th>
<th>SCORE RANGE INT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certified</td>
<td>C</td>
<td>0-7</td>
<td>0-3</td>
</tr>
<tr>
<td>Provisionally Certified</td>
<td>PC</td>
<td>8-14</td>
<td>4-7</td>
</tr>
<tr>
<td>Probation</td>
<td>P</td>
<td>15-40</td>
<td>&gt;7</td>
</tr>
</tbody>
</table>

After the analysis is complete, a report is sent to each laboratory via email. This summary includes the decoded data from that laboratory as received by the Duke VQA, performance on each scoring criterion, and a recommended score. Please contact the Duke VQA (vqa-gen@duke.edu) regarding any questions with this report.

Non-Technical Performance

A lab may receive a penalty due to late submission of data, lack of response to queries, or submitting data with PHI (protected health information) and/or PII (personally identifiable information), or data entry errors summarized in Table 4. Please see the following sections regarding non-technical penalties.
Table 4. Non-technical Penalties and Impact on PT Score

<table>
<thead>
<tr>
<th>Score Points</th>
<th>Penalty Type</th>
<th>Description of Penalty</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>2</td>
<td>Data Timeliness</td>
</tr>
<tr>
<td>Data Timeliness</td>
<td>Data submitted late without requesting an extension</td>
<td></td>
</tr>
<tr>
<td>PC1</td>
<td>4</td>
<td>Data Timeliness</td>
</tr>
<tr>
<td>Data Timeliness</td>
<td>Data submitted late without requesting an extension</td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>4</td>
<td>Data Timeliness</td>
</tr>
<tr>
<td>Data Timeliness</td>
<td>Data submitted late without requesting an extension</td>
<td></td>
</tr>
<tr>
<td>C1</td>
<td>2</td>
<td>Data Query Responsiveness</td>
</tr>
<tr>
<td>Data Query Responsiveness</td>
<td>Not responding to queries about data within one week (5 working days)</td>
<td></td>
</tr>
<tr>
<td>PC1</td>
<td>4</td>
<td>Data Query Responsiveness</td>
</tr>
<tr>
<td>Data Query Responsiveness</td>
<td>Not responding to queries about data within one week (5 working days)</td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>4</td>
<td>Data Query Responsiveness</td>
</tr>
<tr>
<td>Data Query Responsiveness</td>
<td>Not responding to queries about data within one week (5 working days)</td>
<td></td>
</tr>
<tr>
<td>C1</td>
<td>2</td>
<td>Data Submission Containing PHI and/or PII</td>
</tr>
<tr>
<td>Data Submission Containing PHI and/or PII</td>
<td>Laboratory submitted data that contained PHI and/or PII</td>
<td></td>
</tr>
<tr>
<td>PC1</td>
<td>4</td>
<td>Data Submission Containing PHI and/or PII</td>
</tr>
<tr>
<td>Data Submission Containing PHI and/or PII</td>
<td>Laboratory submitted data that contained PHI and/or PII</td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>4</td>
<td>Data Submission Containing PHI and/or PII</td>
</tr>
<tr>
<td>Data Submission Containing PHI and/or PII</td>
<td>Laboratory submitted data that contained PHI and/or PII</td>
<td></td>
</tr>
<tr>
<td>C1</td>
<td>2</td>
<td>Data entry errors</td>
</tr>
<tr>
<td>Data entry errors</td>
<td>Laboratory submitted data with entry errors that were not caught and corrected prior to the PT due date</td>
<td></td>
</tr>
<tr>
<td>PC1</td>
<td>4</td>
<td>Data entry errors</td>
</tr>
<tr>
<td>Data entry errors</td>
<td>Laboratory submitted data with entry errors that were not caught and corrected prior to the PT due date</td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>4</td>
<td>Data entry errors</td>
</tr>
<tr>
<td>Data entry errors</td>
<td>Laboratory submitted data with entry errors that were not caught and corrected prior to the PT due date</td>
<td></td>
</tr>
</tbody>
</table>

1. Data Timeliness

A due date is assigned to each 5-member panel. Data must be submitted via the Duke VQA Web Application by the deadline or data will receive a penalty. A laboratory may request an exemption, extension, or to be placed on hold by emailing vqa-gen@duke.edu. If no contact is made prior to the due date, and the data are received late once within four rounds of testing, then the proficiency testing score will be down-graded one level (i.e. a technical score of C would be assigned a score of C1T, which equates to 2 points for a panel score). If data are received late for the second time in four rounds of testing, then the proficiency testing score will be down-graded two levels (i.e. a technical score of C would be assigned a score of C2T, which equates to 4 points for a panel score).

2. Data Query Responsiveness

Occasionally, a query is sent to a laboratory to clarify or fix a problem noted in their VQA submission. The Duke VQA will email the testing laboratory and ask them to follow up on the query. If the laboratory resolves the query within a week of receiving the original query (5 working days,
excluding any holidays), then no penalty will be assessed. If no resolution is received, a second query will be sent to the testing laboratory and will include affiliated network laboratory coordination center. If the query is not resolved within one week (5 working days excluding holidays) of the second query, then the data will be scored as a minor late query response. A third query will be sent to the testing laboratory, including the VQA manager, and the affiliated network laboratory coordination group. If the problem is still not resolved within one week (5 business days excluding holidays) then a major problem will be assessed. If a minor late query resolution is noted, the proficiency testing score will be down-graded one level (i.e. a technical score of C would be assigned a score of C1<sub>Q</sub>, which equates to 2 points in a panel score; a technical score of PC would be assigned a score of PC1<sub>Q</sub> which equates to 4 points in panel score). If a major late query resolution is noted, then the proficiency testing score will be down-graded two levels (i.e. a technical score of C would be assigned a score of C2<sub>Q</sub>, which equates to 4 points for a panel score). A major late query resolution will receive the maximum of 4 points for a panel score.

3. Data submissions Containing PHI and/or PII

PHI (protected health information), PII (personally identifiable information), or any information that could link submitted data to an individual participant must not be included in any data files submitted to the VQA for analysis.

Note: it is at the discretion of the VQA to reject data sets that are presumed to contain PHI/PII.

When submitting VQA data, the laboratory will be required to attest that the submission does not contain PHI or PII. If, during QA of the data, the VQA finds PHI or PII, a penalty will be assessed. All data that contains PII or PHI will be expunged from the database and laboratories will be required to remove the information and resubmit their data. Data resubmitted after the due date, without an extension request, will also receive a late penalty score.

If a data set contains PHI/PII, the proficiency testing score will be down-graded one level for a first offense (i.e. a technical score of C would be assigned a score of C1<sub>P</sub> for the first incident, which equates to 2 points for a panel score). For subsequent offenses within 4 rounds of testing, the proficiency testing score will be down-graded an additional level (i.e. a technical score of C would be assigned a score of C2<sub>P</sub>, which equates to 4 points for a panel score). Laboratory directors, network coordination centers and the Division of AIDS will be notified if a laboratory submits data containing PHI/PII.

Note: Any combination of penalties (technical or non-technical) will result in a maximum panel score of 4 points (e.g. C1<sub>Q</sub>, PC1<sub>T</sub>, etc).

After the analysis is complete, a report is sent to each laboratory via email. This summary includes the decoded data from that laboratory as received by the Duke VQA, performance on each scoring criterion, and a score. The VQA Advisory Board (VQAAB) reviews the scores of any lab that is having issues and the VQA recommended scores. Please contact the Duke VQA (vqa-gen@duke.edu) regarding any questions with this report.

4. Data Entry Errors

Data for each HIV-1 Drug Resistance PT is submitted using the VQA web-system, which requires upload of FASTA files for each PT sample and a Specimen Mutation File. Participating sites have the ability to save their data in the web-system and review it before submission. Prior to the PT due date, a site may request to re-open their PT to correct data entry errors. However, sites will not be able to correct any data entry errors after the PT due date. Data that is submitted to the VQA that contains
data entry errors such as entering the wrong values, entering data in the wrong location, switching samples, or submitting the wrong file could result in a non-technical penalty.

If a data entry error occurs once within four rounds of testing, the proficiency testing score will be down-graded one level (i.e. a technical score of C would be assigned a score of C1D, which equates to 2 points for a panel score). If a data entry error occurs for the second time in four rounds of testing, then the proficiency testing score will be down-graded two levels (i.e. a technical score of C would be assigned a score of C2D, which equates to 4 points for a panel score) as summarized in Table 4.